The prognostic and predictive value of Tregs and tumor immune subtypes in postmenopausal, hormone receptor-positive breast cancer patients treated with adjuvant endocrine therapy: a Dutch TEAM study analysis

Breast Cancer Research and Treatment

Volumn 149, Issue 3, 2015, Pages 587-596

  Engels, C C ^a   Charehbili, A ^a   van de Velde, C J H ^a   Bastiaannet, E ^a   Sajet, A ^a   Putter, H ^a   van Vliet, E A ^a   van Vlierberghe, R L P ^a   Smit, V T H B M ^a   Bartlett, J M S ^b   Seynaeve, C ^c   Liefers, G J ^a   Kuppen, P J K ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

Adjuvant endocrine therapy; Breast cancer; Prognostic and predictive value; Tumor immune subtypes

Indexed keywords

EXEMESTANE; HLA ANTIGEN CLASS 1; HLA E ANTIGEN; HLA G ANTIGEN; HORMONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR FOXP3; ANDROSTANE DERIVATIVE; ESTROGEN RECEPTOR; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; HLA-E ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; TREATMENT DURATION; TUMOR IMMUNITY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANDROSTADIENES; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; T-LYMPHOCYTES, REGULATORY; TAMOXIFEN;

EID: 84925496959     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3269-7     Document Type: Article

References (37)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108
2. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
3. van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536
4. van de Vijver MJ, He YD, van’t Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
5. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144
6. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53:904–910
7. Bates GJ, Fox SB, Han C et al (2006) Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373–5380
8. de Kruijf EM, Sajet A, van Nes JG et al (2010) HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 185:7452–7459
9. de Kruijf EM, van Nes JG, Sajet A et al (2010) The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 16:1272–1280
10. Liu F, Lang R, Zhao J et al (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645–655
11. Mahmoud SM, Paish EC, Powe DG et al (2011) Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 29:1949–1955
12. Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964
13. de Kruijf EM, Engels CC, van de Water W et al (2013) Tumor immune subtypes distinguish tumor subclasses with clinical implications in breast cancer patients. Breast Cancer Res Treat 142(2):355–364
14. Loi S, Sirtaine N, Piette F et al (2013) Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 31:860–867
15. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93–103
16. Denkert C, Loibl S, Noske A et al (2010) Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28:105–113
17. Behjati S, Frank MH (2009) The effects of tamoxifen on immunity. Curr Med Chem 16:3076–3080
18. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141
19. Thurlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757
20. van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321–331
21. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235
22. Bartlett JM, Brookes CL, Robson T et al (2011) Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. J Clin Oncol 29:1531–1538
23. Powell AG, Horgan PG, Edwards J (2012) The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key? J Cancer Res Clin Oncol 138:723–728
24. Chew SF, Kanaan C, Tait BD (2007) HLA expression and cancer–14th IHIWS immunohistochemistry quality control exercise exchange results. Tissue Antigens 69(Suppl 1):248–251
25. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol 3:999–1005
26. Whiteside TL (2012) What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 22:327–334
27. Whiteside TL (2014) Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol Immunother 63:67–72
28. Baumgarten SC, Frasor J (2012) Minireview: inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 26:360–371
29. Cronstein BN (1985) Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994(76):5–13
30. Xie W, Duan R, Safe S (1999) Estrogen induces adenosine deaminase gene expression in MCF-7 human breast cancer cells: role of estrogen receptor-Sp1 interactions. Endocrinology 140:219–227
31. Chan MS, Wang L, Felizola SJ et al (2012) Changes of tumor infiltrating lymphocyte subtypes before and after neoadjuvant endocrine therapy in estrogen receptor-positive breast cancer patients—an immunohistochemical study of Cd8 + and Foxp3 + using double immunostaining with correlation to the pathobiological response of the patients. Int J Biol Markers 27:e295–e304
32. Generali D, Bates G, Berruti A et al (2009) Immunomodulation of FOXP3 + regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 15:1046–1051
33. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108
34. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092
35. Takenaka M, Seki N, Toh U et al (2013) FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis. Mol Clin Oncol 1:625–632
36. Marin R, Ruiz-Cabello F, Pedrinaci S et al (2003) Analysis of HLA-E expression in human tumors. Immunogenetics 54:767–775
37. Rouas-Freiss N, Moreau P, Ferrone S, Carosella ED (2005) HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism? Cancer Res 65:10139–10144